Fender criticises stadium pricing, calling it ‘bollocks’ and says it ‘won’t be happening’ on his tour Sam Fender has responded to criticism by fans about ticket prices for his 2027 stadium tour by promising he would lower the cost, telling followers on Instagram: “They’re getting changed.” The 32-year-old musician announced his Proper Massive stadium tour earlier this week. Continue reading...
Sam Fender tells fans high ticket prices for Proper Massive tour are ‘getting changed’
Source: The Guardian
Original reporting
The Guardian: read the full reportRelated stories
BBC Business3 outlets
Rosebank: Life on the oil field at the centre of a political storm
Scotland editor James Cook finds out what life is like on board a ship in an untapped oil field awaiting its fate.
The Guardian2 outlets
Healey’s first budget to include big devolution package to boost growth
Chancellor will build on Burnham’s promise that local leaders in England will no longer have to ‘come cap in hand to Westminster’ Andy Burnham has promised that local leaders in England will no longer have to come “cap in hand to Westminster” ahead of a fresh drive to devolve spending power in next week’s budget. In his statement on Wednesday, the chancellor, John Healey, will include plans for a new £1.5bn borrowing facility, to be drawn up in collaboration with mayors over the next two years. Continue reading...
CNBC
American embassies tighten security as Iran threat warnings intensify ahead of U.S. midterm elections
A memo from DNI director Jay Clayton said Iran is in the "advanced stages" of planning attacks against Americans.
CNBC
After SpaceX restores high-speed service, Musk claims Ukraine violated Starlink agreement
Ukraine says restrictions on Starlink and Starshield have been lifted, restoring connectivity to fast-moving military systems after disruptions.
CNBC
Democrats, voting-rights groups challenge Trump's bid to block Alaska Senate certification
Lawsuits filed by candidate Mary Peltola and a voters' rights group challenge Trump's preemptive efforts to block a Democratic Senate victory in Alaska.
CNBC
Biotech stocks are surging. How investors can play the new drug innovation boom
Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.